July 28 is World Hepatitis Day. This year’s theme is "Hepatitis-free Future". In response to the call of the World Health Organization, the Medical Federation and the China United Liver Health Promotion Center have joined hands in Gilead’s With strong support, we will jointly hold the second free liver disease screening free clinic nationwide to promote the screening, testing and treatment of viral hepatitis in our country, raise the public’s awareness of prevention and treatment, and enable patients to be identified and treated early. The prevention and treatment of hepatitis has been carried out in a comprehensive, in-depth and solid manner.

  On July 27, Dongguan Donghua Hospital carried out liver disease screening tests for the public in the hospital early in the morning. The people who came for the test wore masks and lined up neatly to conduct free liver disease screening in an orderly manner. According to the relevant person in charge of the Medical Federation, the event was carried out in batches in 217 hospitals in 126 cities in 29 provinces across the country. The hospitals that signed up for the event were all over the country, including the West China Fourth Hospital of Sichuan University and the Third People’s Hospital of Shenzhen. Hospitals, Xi'an Central Hospital, the First Affiliated Hospital of Xiamen University, and the Second Xiangya Hospital of Central South University, etc., the entire screening activity will last from July 23 to August 8.

  Liu Guizhang, the chief physician of Dongguan Donghua Hospital who participated in this free hepatitis screening activity, said, “At present, hepatitis B and C together are the most common cause of death for patients with liver disease, and 1.4 million people lose their lives every year. In the current COVID In the context of the -19 pandemic, viral hepatitis still kills thousands of people every day. Therefore, it is particularly necessary to conduct large-scale hepatitis screening tests nationwide every year."

  According to statistics, as a major viral hepatitis country, one third of the 240 million chronic hepatitis B virus infections in the world are in China, and there are also 7.6 million hepatitis C patients. Most of these patients have not been tested and treated, and may develop serious diseases such as liver cirrhosis and liver tumors in the future, causing a huge social and family burden. And although China has included hepatitis B vaccine as part of China's neonatal immunization program, the coverage rate of hepatitis B vaccine in the newborn population has reached more than 90%, and the successful blocking rate of mothers and infants has reached 95%, but the number of new cases is increasing and the number is huge. The number of patients in China determines that China will remain a major hepatitis country in the world in the short term. Moreover, the annual medical expenses for the prevention and treatment of viral hepatitis and related liver diseases in my country are as high as 100 billion yuan or more.

  As the leading chronic disease management platform in China, as early as the beginning of 2018, the Medical Federation began to cooperate with Gilead on related research in the field of chronic liver disease management, and carried out a series of chronic liver disease prevention and treatment work. After more than two years of hard work, more than 6,000 liver disease doctors have managed about 80,000 liver disease patients on the medical federation platform. They have opened up the field of disease screening, doctor education, patient management, patient follow-up, electronic prescription, and DTP distribution. In many links such as patient payment, a successful model of the whole process management of a single disease has emerged. In addition, the Medical Federation has also invested in the development of the "Chronic Hepatitis B Real World Big Data Research Platform" in the field of chronic diseases, aiming to establish a standardized, efficient and innovative real-world data research system, promote the output of high-quality research evidence, and improve The research level of chronic hepatitis B in China has broken through the bottleneck of clinical scientific research, and at the same time, it allows liver disease doctors to realize their own team's clinical scientific research improvement and harvest on the platform.

  At present, the Medical Federation platform has gathered more than 800,000 real-name certified doctors and more than 50,000 contracted doctors across the country. In addition to liver disease, the diseases of chronic disease management also cover diabetes, HIV, tumor, chronic kidney disease, cardiovascular and cerebrovascular diseases, and pediatrics. , Psychology, respiratory and asthma, traditional Chinese medicine and other chronic diseases and disciplines, to provide patients with a series of effective, low-cost and accessible treatment suggestions, treatment effect evaluation, electronic prescriptions, medication guidance, psychological counseling, and lifestyle interventions Out-of-hospital chronic disease management services enable patients’ diseases to be effectively controlled, thereby improving the quality of life of patients.